Tobin Schilke - 31 Jan 2023 Form 4 Insider Report for Revance Therapeutics, Inc.

Role: CFO
Signature: /s/ Dwight Moxie, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 31 Jan 2023
Net transactions value: -$110,755
Form type: 4
Filing time: 02 Feb 2023, 20:38:15 UTC
Previous filing: 23 Jan 2023
Next filing: 16 Feb 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RVNC	Common Stock	Sale	$110,755	-3,201	-5.5%	$34.60	54,676	01 Feb 2023	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RVNC	Employee Stock Option (Right to Buy)	Award	$0	+50,435		$0.000000	50,435	31 Jan 2023	Common Stock	50,435	$34.68	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan dated November 18, 2022 by Mr. Schilke.
F2	Includes 2,953 shares purchased pursuant to the Issuer's 2014 Employee Stock Purchase Plan.
F3	The shares subject to the stock option shall vest in forty-eight (48) equal monthly installments beginning from January 31, 2023, subject to Mr. Schilke's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each vesting date.